Strategic partnerships Arbutus Biopharma is actively pursuing collaborations and has engaged in high-profile IP actions and partnerships, including a global settlement with Moderna and ongoing patent infringement actions. This indicates a receptiveness to strategic alliances and potential co-development or licensing opportunities around infectious disease therapies and RNAi platforms.

HBV focus The company concentrates on chronic hepatitis B virus therapies with imdusiran and AB-101, signaling a target-rich opportunity for agents that complement or accelerate HBV treatment pipelines, diagnostics, or companion therapeutics for virology and hepatology portfolios.

Clinical stage As a clinical-stage biopharma with ongoing trials and a recent expansion of leadership, Arbutus presents a chance to engage in early to mid-stage partnering strategies, potential advisory roles, and joint development discussions to advance imdusiran and AB-101.

Data and events Regular appearances at major conferences (AASLD, EASL) and data presentations create recurring touchpoints for outreach, sponsorships, and collaboration opportunities around their advancing RNAi and PD-L1 inhibitor programs.

Growth signals With a funding profile of $354M, revenue in the lower mid-range, and leadership changes including a new CEO, there is an openness to new commercial strategy, licensing, or co-development deals to scale toward later-stage milestones and potential product launches.